TY - JOUR
T1 - Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals
T2 - Two randomized trials
AU - Conant, M. A.
AU - Schacker, T. W.
AU - Murphy, R. L.
AU - Gold, J.
AU - Crutchfield, L. T.
AU - Crooks, R. J.
PY - 2002
Y1 - 2002
N2 - Our objective was to evaluate valaciclovir for anogenital herpes in HIV-infected individuals using 2 controlled trials conducted before highly active antiretroviral therapy (HAART) was used. In Study 1, 1062 patients (CD4+ ≥ 100cells/mm3) received suppressive valaciclovir or aciclovir for one year and were assessed monthly. In Study 2, 467 patients were treated episodically for ≥5days with valaciclovir or aciclovir and evaluated daily. Valaciclovir was as effective as aciclovir for suppression and episodic treatment of herpes. Hazard ratios [95% confidence interval (CI)] for time to recurrence for valaciclovir 500mg twice daily and 1000mg once daily vs aciclovir were 0.73 [0.50, 1.06], P=0.10, and 1.31 [0.94, 1.82], P=0.11. Valaciclovir 500mg twice daily was superior to 1000mg once daily, P=0.001. Valaciclovir 1000 mg twice daily was comparable to aciclovir on herpes episode duration (hazard ratio 0.92 [0.75, 1.14]). Adverse events were similar among treatments. In conclusion, valaciclovir is a safe, effective, convenient alternative to aciclovir for HSV infection in HIV-infected individuals.
AB - Our objective was to evaluate valaciclovir for anogenital herpes in HIV-infected individuals using 2 controlled trials conducted before highly active antiretroviral therapy (HAART) was used. In Study 1, 1062 patients (CD4+ ≥ 100cells/mm3) received suppressive valaciclovir or aciclovir for one year and were assessed monthly. In Study 2, 467 patients were treated episodically for ≥5days with valaciclovir or aciclovir and evaluated daily. Valaciclovir was as effective as aciclovir for suppression and episodic treatment of herpes. Hazard ratios [95% confidence interval (CI)] for time to recurrence for valaciclovir 500mg twice daily and 1000mg once daily vs aciclovir were 0.73 [0.50, 1.06], P=0.10, and 1.31 [0.94, 1.82], P=0.11. Valaciclovir 500mg twice daily was superior to 1000mg once daily, P=0.001. Valaciclovir 1000 mg twice daily was comparable to aciclovir on herpes episode duration (hazard ratio 0.92 [0.75, 1.14]). Adverse events were similar among treatments. In conclusion, valaciclovir is a safe, effective, convenient alternative to aciclovir for HSV infection in HIV-infected individuals.
KW - HIV
KW - Herpes simplex virus
KW - Recurrent genital herpes
KW - Valaciclovir
UR - http://www.scopus.com/inward/record.url?scp=18244396615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18244396615&partnerID=8YFLogxK
U2 - 10.1258/0956462021924550
DO - 10.1258/0956462021924550
M3 - Article
C2 - 11802924
AN - SCOPUS:18244396615
VL - 13
SP - 12
EP - 21
JO - International Journal of STD and AIDS
JF - International Journal of STD and AIDS
SN - 0956-4624
IS - 1
ER -
